Skip to main navigation Skip to search Skip to main content

A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalDefault journal
StatePublished - Jun 1 2021

Cite this